US Federal Senate Bill SB2532

US Federal 2025-2026 Regular Session

• Introduced: 7/30/25
• Refer: 7/30/25

Caption

Safe Response Act

Summary

The Safe Response Act would reauthorize and update the federal First Responder Training Program under section 546 of the Public Health Service Act. The bill keeps the program focused on training first responders to respond to drug overdoses and related emergencies, while modernizing the statutory language to cover medical products that are “approved, cleared, or otherwise legally marketed” rather than only those approved or cleared. It also makes several conforming edits that remove repeated references to “opioid” and broaden some references from “opioid and heroin” to “opioid, heroin, and other drug,” as well as from “opioid overdose” to “overdose.” The bill also increases the authorization of appropriations for the program from $36 million annually for fiscal years 2019 through 2023 to $57 million annually for fiscal years 2026 through 2030. In practical terms, that would extend federal support for training police, firefighters, emergency medical personnel, and other first responders in overdose recognition, naloxone use, and related emergency response practices, while allowing the program to address a wider range of drug-related incidents beyond opioids alone.

Impact

If enacted, the bill would amend section 546 of the Public Health Service Act, updating the scope and terminology of the First Responder Training Program and extending its funding authorization through fiscal year 2030. The changes would affect federal public health law and the agencies or grantees administering first responder training grants, with likely downstream effects on state and local emergency response training programs that rely on federal support. It would also expand the program’s statutory framing from a narrower opioid-specific focus to a broader overdose and drug-response framework.

Sentiment

The available record suggests generally supportive sentiment. The bill was introduced by Senators Baldwin, Hassan, and Capito, indicating bipartisan sponsorship, and its purpose is framed as a reauthorization and modernization measure rather than a controversial policy shift. No committee transcript or vote record is available here, but the text itself reflects a continuation of an existing program with increased funding and broader applicability, which typically draws support from public health and emergency response stakeholders.

Contention

The main substantive point of potential contention is the expansion from opioid-specific language to broader references to overdose and other drugs. Supporters are likely to view this as a necessary update to reflect current drug trends and emergency response needs, while critics could question whether the program should remain narrowly targeted to opioids or whether the increased authorization level is justified. Another possible issue is the higher funding authorization, which may draw scrutiny from fiscal conservatives even though the bill does not itself appropriate funds.